AHK-Cu: The Hair Follicle Copper Peptide, Examined

TL;DR

AHK-Cu is a copper-binding tripeptide studied mainly in human hair-follicle and cell cultures. One published study reported follicle elongation and changes in dermal papilla cells, but that is not the same as proving hair growth in people. There are no published human randomised trials specific to AHK-Cu. Its evidence base is much thinner than GHK-Cu's, so conclusions should stay cautious.

What is AHK-Cu?

AHK-Cu — L-alanyl-L-histidyl-L-lysine complexed with copper(II), also referenced in cosmetic-ingredient literature as Copper Tripeptide-3 — is a synthetic copper-binding tripeptide in the same broad family as GHK-Cu (Copper Tripeptide-1). The two are structurally related but distinct: GHK-Cu's sequence is glycyl-L-histidyl-L-lysine, while AHK-Cu substitutes alanine for glycine as the first residue. Both peptides chelate a copper(II) ion, but they have been studied through separate, and very differently sized, bodies of research.

AHK-Cu's research profile is narrower and more recent than GHK-Cu's. The compound is discussed almost entirely in the context of a single landmark study that examined its effects on human hair follicles and dermal papilla cells directly alongside GHK-Cu. This guide is for educational and research purposes only. Not medical advice, and the compound is not approved for human therapeutic use.

How strong is the evidence?

The following table summarises the current types of evidence available for AHK-Cu in scientific literature.

How does AHK-Cu work?

Like GHK-Cu, AHK-Cu is studied as a copper-delivery tripeptide: it complexes a copper(II) ion and is investigated for its ability to influence cellular signalling in skin and hair follicle tissue. The identified research examined AHK-Cu's effects on dermal papilla cells (the signalling cells at the base of the hair follicle that regulate the hair growth cycle) and on dermal fibroblasts.

In that research, AHK-Cu at low (picomolar to nanomolar range) concentrations was reported to increase proliferation of both dermal papilla cells and dermal fibroblasts, to increase fibroblast production of vascular endothelial growth factor (VEGF) — a signalling protein linked to blood supply to the follicle — and to decrease fibroblast secretion of transforming growth factor-beta1 (TGF-β1), a protein associated with suppressing the hair growth (anagen) phase. The proposed mechanism is that supporting dermal papilla and fibroblast activity, while reducing a growth-suppressing signal, creates conditions more favourable to hair follicle growth — but this remains a proposed mechanism from a single body of tissue-culture research, not an established clinical mechanism.

What has AHK-Cu been studied for?

Hair Follicle Elongation (Ex Vivo Organ Culture)

The primary published research cultured human hair follicles ex vivo and reported that AHK-Cu, applied across a range of low concentrations, stimulated elongation of the follicles compared with untreated controls — used by the study's authors as a marker of a hair-growth-promoting effect in this tissue-culture model.

Dermal Papilla Cell Proliferation

In cultured human dermal papilla cells, AHK-Cu was reported to increase cell proliferation. Because dermal papilla cells regulate whether a follicle stays in its growth phase, increased proliferation of these cells is the mechanistic link the study's authors drew to the observed follicle elongation.

Dermal Fibroblast & Growth-Factor Signalling

The same body of research reported that AHK-Cu increased proliferation of human dermal fibroblasts, increased fibroblast VEGF output, and decreased fibroblast secretion of TGF-β1 — a combination the authors interpreted as supportive of a more growth-favourable follicle environment.

Compared With GHK-Cu in the Same Research

The identified study examined AHK-Cu and GHK-Cu side by side in the same hair-follicle and cell-culture models, and reported broadly similar directional effects for both compounds in that setting. Importantly, this single study is essentially the entire published evidence base specifically for AHK-Cu. GHK-Cu, by contrast, has a much larger and more varied separate research literature — including topical human studies, animal wound-healing models, and anti-inflammatory research — covered in full in the GHK-Cu Research Guide. Readers should not assume findings from GHK-Cu's broader literature automatically transfer to AHK-Cu.

What did the studies actually find?

What has AHK-Cu been studied alongside?

• AHK-Cu + RU58841 → Research rationale discussed in hair-health contexts by the same logic as the established GHK-Cu + RU58841 Hair Health Stack: pairing a local DHT-sensitivity blocker (RU58841) with a copper tripeptide studied for dermal papilla and follicle-tissue signalling. AHK-Cu has not been studied together with RU58841 in any identified dedicated trial — this is a separate, thinner-evidence variant of the GHK-Cu pairing, not the same studied combination.

⚠️ Stack combinations listed for research reference only. Not safety or efficacy guidance.

Honest Limitations

AHK-Cu's hair-specific research base is thin compared with GHK-Cu's. The identified evidence is a single study examining AHK-Cu in ex vivo human hair follicle organ culture and in vitro dermal papilla cell and fibroblast culture. There are no published human RCTs, no identified animal-model studies specific to AHK-Cu, and no dedicated trial pairing AHK-Cu with RU58841 or any other compound. This is a meaningfully smaller evidence base than GHK-Cu's, which includes human topical RCTs, extensive animal wound-healing work, and a separate hair-follicle organ-culture literature of its own. Anyone researching AHK-Cu should treat the current evidence as early-stage and preliminary, and should not read across conclusions from GHK-Cu's broader literature as if they automatically apply to AHK-Cu.

What side effects were reported?

Because AHK-Cu's published research is limited to ex vivo and in vitro tissue-culture work, no human safety or tolerability data has been established through clinical trials. Copper-tripeptide complexes as a class — including the far better studied GHK-Cu — have generally been reported to cause localised irritation at the site of topical application in research settings, but this has not been specifically documented for AHK-Cu in human use.

Long-term human safety data for AHK-Cu has not been established through large-scale trials — this is a meaningful research gap, not a demonstrated safety profile. Researchers should treat the limited evidence base as a significant caveat.

AHK-Cu at a glance

Also Known As

Copper Tripeptide-3, L-alanyl-L-histidyl-L-lysine-copper(II)

Classification

Synthetic copper-binding tripeptide (GHK-Cu analogue — alanine substituted for glycine)

Route Studied

Ex vivo organ culture and in vitro cell culture only — no identified published research via systemic, injectable, or oral routes

Regulatory Status

Not approved by HPRA, FDA, or EMA as a medicine; appears in cosmetic-formulation ingredient literature

Research Classification

Copper Chelator, Investigational (Preliminary)

The research this page cites

• Pyo HK et al. 2007 — The effect of tripeptide-copper complex on human hair growth in vitro. — Archives of pharmacal research — [Evidence type: Ex vivo organ culture / In vitro]
• PubMed: full AHK-Cu research literature search →
• Full GHK-Cu Research Guide →
• Full RU58841 Research Guide →
• GHK-Cu + RU58841 Hair Health Stack Guide →